EUVIMEDOpdag EUVIMED
Crossref

Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries

Barbara Burgos-Blasco, Julian García-Feijóo, Cristina Gines-Gallego, Lucía Perucho-Gonzalez, Jose Ignacio Fernandez-Vigo, Jose María Martinez de la Casa, Federico Saenz-Frances, Laura Morales-Fernandez, Carmen Dora Mendez-Hernandez

Graefe's Archive for Clinical and Experimental Ophthalmology · 2023-05 · 261 (5) · 1349-1357

DOI: 10.1007/s00417-022-05939-5 ↗

At a glance

Journal article in Graefe's Archive for Clinical and Experimental Ophthalmology, published online on 2022-12-20. Written by Barbara Burgos-Blasco and 8 co-authors. Institution: Servicio de Oftalmología, Instituto de Investigación Sanitaria, Hospital Clínico San Carlos (IdISSC), Hospital Clinico San Carlos, Madrid, Spain. bbu…. Major MEDLINE topics: Glaucoma, Trabeculectomy, Glaucoma Drainage Implants. Cited 13 times so far (Crossref); 20 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

PURPOSE: This study aims to evaluate the efficacy and safety of the PreserFlo MicroShunt (Santen, Osaka, Japan) in lowering intraocular pressure (IOP) in childhood glaucoma patients with previous failed glaucoma surgeries. METHODS: This is a prospective case review of consecutive PreserFlo procedures performed in childhood glaucoma patients after failed surgeries. Age, sex, diagnosis, and previous glaucoma surgeries, as well as visual acuity, IOP, and treatment in the preoperative visit and all follow-up visits were collected. Outcome measures included IOP reduction from baseline, mean IOP change from baseline at month 6, medication use at 6 months, complications, adverse events, and need for further procedures. RESULTS: Fourteen patients were included, 8 (57%) males and 6 (43%) females; the mean age was 27.5 ± 13.5 years. Nine patients (64%) had at least two trabeculectomies, and 6 patients (43%) had at least one trabeculectomy and a glaucoma drainage implant. The mean IOP change from baseline was 11.3 ± 4.9 mmHg at 12 months. At 12 months, 12 patients (86%) presented ≥ 20% IOP lowering from baseline, and 11 patients (79%) presented ≥ 30%. The mean medication count decreased from 3.9 ± 0.7 (baseline) to 0.7 ± 1.3 (12 months). No intraoperative complications were reported. No adverse events were noted. No secondary filtration surgery was required, although bleb needling was required in one case, 1 month after the surgery. CONCLUSIONS: PreserFlo with MMC can be used successfully to treat uncontrolled IOP in childhood glaucoma cases with previous failed surgeries. Larger studies with longer follow-up are needed to further explore the role of the device in resistant childhood glaucoma cases.

Subjects

MeSH terms (MEDLINE)

GlaucomaTrabeculectomyGlaucoma Drainage ImplantsMaleFemaleHumansAdolescentYoung AdultAdultMitomycinIntraocular PressureTreatment Outcome

Author keywords

Childhood glaucomaMinimally invasive glaucoma surgeryPreserflo implant

Substances

Mitomycin

Authors and institutions

  • Servicio de Oftalmología, Instituto de Investigación Sanitaria, Hospital Clínico San Carlos (IdISSC), Hospital Clinico San Carlos, Madrid, Spain. bburgos171@hotmail.com.
  • Servicio de Oftalmología, Instituto de Investigación Sanitaria, Hospital Clínico San Carlos (IdISSC), Hospital Clinico San Carlos, Madrid, Spain.
  • Departamento de Inmunología, Oftalmología Y ORL, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

Cite

APA

Burgos-Blasco, B., García-Feijóo, J., Gines-Gallego, C., Perucho-Gonzalez, L., Fernandez-Vigo, J. I., Martinez de la Casa, J. M., Saenz-Frances, F., Morales-Fernandez, L., & Mendez-Hernandez, C. D. (2023). Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries. Graefe's Archive for Clinical and Experimental Ophthalmology, 261(5), 1349-1357. https://doi.org/10.1007/s00417-022-05939-5

Vancouver

Burgos-Blasco B, García-Feijóo J, Gines-Gallego C, Perucho-Gonzalez L, Fernandez-Vigo JI, Martinez de la Casa JM, et al. Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries. Graefe's Archive for Clinical and Experimental Ophthalmology. 2023;261(5):1349-1357. doi:10.1007/s00417-022-05939-5

BibTeX
@article{BurgosBlasco2023,
  author = {Burgos-Blasco, Barbara and García-Feijóo, Julian and Gines-Gallego, Cristina and Perucho-Gonzalez, Lucía and Fernandez-Vigo, Jose Ignacio and Martinez de la Casa, Jose María and Saenz-Frances, Federico and Morales-Fernandez, Laura and Mendez-Hernandez, Carmen Dora},
  title = {Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2023},
  volume = {261},
  number = {5},
  pages = {1349--1357},
  doi = {10.1007/s00417-022-05939-5}
}
Start for free →